Rotigotine controlled release - Serina Therapeutics

Drug Profile

Rotigotine controlled release - Serina Therapeutics

Alternative Names: SER-214

Latest Information Update: 29 Dec 2015

Price : $50

At a glance

  • Originator Serina Therapeutics
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 Phase-I clinical trials in Parkinson's disease (Early-stage disease) in USA (SC)
  • 26 Oct 2015 SER 214 is available for licensing as of 26 Oct 2015. http://www.serinatherapeutics.com./pipeline/#ser-214
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top